| scholarly article | Q13442814 |
| P50 | author | Ines De Pauw | Q91077596 |
| Andreas Domen | Q91643118 | ||
| Julie Jacobs | Q59662550 | ||
| Sven De Bruycker | Q59666259 | ||
| Christophe Deben | Q85496626 | ||
| An Wouters | Q38324398 | ||
| Filip Lardon | Q38324438 | ||
| Jolien Van den Bossche | Q40933783 | ||
| P2093 | author name string | Patrick Pauwels | |
| Marc Peeters | |||
| Pol Specenier | |||
| Jan Baptist Vermorken | |||
| P2860 | cites work | Polo-like kinase 1 inhibitor BI 6727 induces DNA damage and exerts strong antitumor activity in small cell lung cancer | Q91005196 |
| Polo-like kinase 1 inhibition in NSCLC: mechanism of action and emerging predictive biomarkers | Q91906639 | ||
| Therapeutic potential of PLK1 inhibition in triple-negative breast cancer | Q93163293 | ||
| p53 is not directly relevant to the response of Polo-like kinase 1 inhibitors | Q95435891 | ||
| Plk1 inhibition causes post-mitotic DNA damage and senescence in a range of human tumor cell lines | Q27334288 | ||
| BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity | Q27655038 | ||
| ColonyArea: an ImageJ plugin to automatically quantify colony formation in clonogenic assays | Q28364520 | ||
| PLK1 blockade enhances therapeutic effects of radiation by inducing cell cycle arrest at the mitotic phase | Q30670722 | ||
| Towards Prognostic Profiling of Non-Small Cell Lung Cancer: New Perspectives on the Relevance of Polo-Like Kinase 1 Expression, the TP53 Mutation Status and Hypoxia | Q33820876 | ||
| Cellular senescence: from physiology to pathology | Q34041305 | ||
| Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy | Q34106830 | ||
| Polo-like kinase 1 (PLK1) inhibition suppresses cell growth and enhances radiation sensitivity in medulloblastoma cells | Q34184864 | ||
| Clonogenic assay of cells in vitro. | Q34615431 | ||
| Tumor cell senescence in cancer treatment | Q35143435 | ||
| Cytotoxic mechanism of PLK1 inhibitor GSK461364 against osteosarcoma: Mitotic arrest, apoptosis, cellular senescence, and synergistic effect with paclitaxel | Q35900060 | ||
| Polo-like Kinase 1 as a potential therapeutic target in Diffuse Intrinsic Pontine Glioma | Q36107521 | ||
| Phase I trial of volasertib, a Polo-like kinase inhibitor, in Japanese patients with acute myeloid leukemia | Q36467485 | ||
| Evaluation of Polo-like kinase 1 as a potential therapeutic target in Merkel cell carcinoma | Q50897647 | ||
| Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer | Q50970713 | ||
| Hallmarks of Cellular Senescence | Q51767478 | ||
| The vanillin derivative 6-bromine-5-hydroxy-4-methoxybenzaldehyde induces aberrant mitotic progression and enhances radio-sensitivity accompanying suppression the expression of PLK1 in esophageal squamous cell carcinoma | Q52572930 | ||
| PLK1 inhibition radiosensitizes breast cancer cells, but shows low efficacy as monotherapy or in combination with other cytotoxic drugs | Q52679900 | ||
| The polo-like kinase 1 inhibitor volasertib synergistically increases radiation efficacy in glioma stem cells | Q52726729 | ||
| BI2536 induces mitotic catastrophe and radiosensitization in human oral cancer cells. | Q55361105 | ||
| Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Q57051777 | ||
| Senescence and senotherapeutics: a new field in cancer therapy | Q57169113 | ||
| Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up† | Q59587188 | ||
| Counting clonogenic assays from normoxic and anoxic irradiation experiments manually or by using densitometric software | Q60531416 | ||
| In vitro study of the Polo-like kinase 1 inhibitor volasertib in non-small-cell lung cancer reveals a role for the tumor suppressor p53 | Q64073233 | ||
| A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents | Q78125095 | ||
| Two-Step Senescence-Focused Cancer Therapies | Q88731404 | ||
| Chemotherapy-induced senescent cancer cells engulf other cells to enhance their survival | Q90147993 | ||
| Tumor cell escape from therapy-induced senescence | Q90701111 | ||
| Targeted anti-mitotic therapies: can we improve on tubulin agents? | Q36717905 | ||
| Inhibition of polo-like kinase 1 in glioblastoma multiforme induces mitotic catastrophe and enhances radiosensitisation | Q37126130 | ||
| Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy | Q37776652 | ||
| Polo-like kinase 1 inhibitors and their potential role in anticancer therapy, with a focus on NSCLC. | Q37946343 | ||
| Polo-like kinase-1 in DNA damage response | Q38199282 | ||
| Polo-like kinases: structural variations lead to multiple functions | Q38222354 | ||
| International patterns of radiotherapy practice for non-small cell lung cancer | Q38378139 | ||
| TP53 and MDM2 genetic alterations in non-small cell lung cancer: Evaluating their prognostic and predictive value | Q38674999 | ||
| Radiosensitization in esophageal squamous cell carcinoma: Effect of polo-like kinase 1 inhibition. | Q38788138 | ||
| Spotlight on Volasertib: Preclinical and Clinical Evaluation of a Promising Plk1 Inhibitor | Q38824242 | ||
| The MDM2-inhibitor Nutlin-3 synergizes with cisplatin to induce p53 dependent tumor cell apoptosis in non-small cell lung cancer | Q38858580 | ||
| Lung cancer: current therapies and new targeted treatments | Q38940816 | ||
| BI 6727 and GSK461364 suppress growth and radiosensitize osteosarcoma cells, but show limited cytotoxic effects when combined with conventional treatments. | Q38968990 | ||
| PLK1-inhibition can cause radiosensitization or radioresistance dependent on the treatment schedule | Q39026552 | ||
| Simultaneous PLK1 inhibition improves local tumour control after fractionated irradiation | Q39119787 | ||
| In vitro targeting of Polo-like kinase 1 in bladder carcinoma: comparative effects of four potent inhibitors | Q39136346 | ||
| Inhibition of polo-like kinase 1 induces cell cycle arrest and sensitizes glioblastoma cells to ionizing radiation. | Q39146648 | ||
| Overexpression of polo-like kinase 1 and its clinical significance in human non-small cell lung cancer | Q39446780 | ||
| Polo-like kinase 1 as predictive marker and therapeutic target for radiotherapy in rectal cancer | Q39687832 | ||
| Sensitivity of cancer cells to Plk1 inhibitor GSK461364A is associated with loss of p53 function and chromosome instability | Q39689315 | ||
| Escape from therapy-induced accelerated cellular senescence in p53-null lung cancer cells and in human lung cancers. | Q40439787 | ||
| Radiation-induced senescence-like growth arrest requires TP53 function but not telomere shortening | Q40836730 | ||
| Plk1: unexpected roles in DNA replication | Q42103005 | ||
| DNA damage is able to induce senescence in tumor cells in vitro and in vivo. | Q43931306 | ||
| Downregulation of Polo-Like Kinase 1 Induces Cellular Senescence in Human Primary Cells Through a p53-Dependent Pathway | Q44403998 | ||
| The Dual Role of Cellular Senescence in Developing Tumors and Their Response to Cancer Therapy. | Q47132545 | ||
| Inhibiting Polo-like Kinase 1 (PLK1) enhances radiosensitization via modulating DNA repair proteins in non-small cell lung cancer | Q47638797 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 12 | |
| P577 | publication date | 2019-11-28 | |
| P1433 | published in | Cancers | Q27722963 |
| P1476 | title | Radiosensitization of Non-Small Cell Lung Cancer Cells by the Plk1 Inhibitor Volasertib Is Dependent on the p53 Status | |
| P478 | volume | 11 |
| Q99403346 | Dual targeting of Polo-like kinase 1 and baculoviral inhibitor of apoptosis repeat-containing 5 in TP53-mutated hepatocellular carcinoma | cites work | P2860 |
Search more.